Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2008, vol. 17, nr 2, March-April, p. 161–166

Publication type: original article

Language: English

Increased Plasma Neuropeptide Y Concentration in Elderly Subjects

Zwiększone stężenie neuropeptydu Y w osoczu u osób w wieku podeszłym

Marcin Adamczak1,, Ewa Rzepka2,, Urszula Spiechowicz−Zatoń1,, Andrzej Więcek1,

1 Department of Nephrology, Endocrinology, and Metabolic Diseases, Medical University of Silesia, Katowice, Poland

2 Emergency Department, Klimontowicza General Hospital, Gorlice, Poland

Abstract

Background. It is well known that aging is associated with several hormonal and metabolic alterations. Elderly patients are also characterized by increased activity of the sympathetic nervous system. As neuropeptide Y (NPY) is a mediator of the sympathetic nervous system.
Objectives. The aim of the present study was to determine the plasma NPY concentration in elderly subjects.
Material and Methods. Sixty apparently healthy elderly subjects 65–93 years old were included in this study. They were divided into two groups: those between 65 and 80 years old and those older than 80. The control group consisted of 57 apparently healthy younger subjects 20–64 years old. Plasma NPY concentration was measured by radioimmunoassay in blood samples drawn three times in one day, at 8 a.m., 4 p.m., and midnight.
Results. Plasma NPY concentration was significantly higher in the subjects between 65 and 80 and those older than 80 years than in the subjects younger than 65. In the entire studied group, significant positive correlations were found between the plasma NPY concentrations measured at 8 a.m., 4 p.m., and midnight and age.
Conclusion. Elderly subjects are characterized by significantly elevated plasma NPY concentration.

Streszczenie

Wprowadzenie. U osób w wieku podeszłym stwierdza się liczne zmiany hormonalne i metaboliczne w porównaniu z osobami młodszymi. Dla osób w wieku podeszłym jest również charakterystyczne zwiększenie aktywności współczulnego układu nerwowego. Uważa się, że neuropeptyd Y jest jednym z przekaźników współczulnego układu nerwowego.
Cel pracy. Ustalenie stężenia neuropeptydu Y w osoczu u osób w wieku podeszłym.
Materiał i metody. Badaniem objęto 60 zdrowych osób w wieku 65–93 lat. Osoby te ze względu na wiek zostały przydzielone do 2 grup: w wieku 65–80 lat oraz powyżej 80 lat. Grupę kontrolną stanowiło 57 osób zdrowych w wieku 20–64 lat. U każdej osoby próbki krwi do oznaczenia stężenia neuropeptydu Y w osoczu pobierano 3−krotnie: o godz. 8.00, 16.00 i 24.00. Stężenie neuropeptydu Y w osoczu oznaczono za pomoca metody radioimmunoenzymatycznej.
Wyniki. Stężenie neuropeptydu Y w osoczu o godz. 8.00; 16.00 i 24.00 było istotnie większe u osób w wieku 65–80 lat i powyżej 80 lat w porównaniu z osobami młodszymi niż 65 lat. Analizując całą grupę badaną, stwierdzono występowanie istotnej dodatniej korelacji między stężeniem neuropeptydu Y w osoczu a wiekiem.
Wnioski. W porównaniu z osobami młodszymi osoby zdrowe w podeszłym wieku charakteryzują się zwiększonym stężeniem NPY w osoczu.

Key words

neuropeptide Y, aging, elderly

Słowa kluczowe

neuropeptyd Y, starzenie, wiek podeszły

References (27)

  1. Lamberts SWJ, van den Beld A, van der Lely A: The endocrinology of aging. Science 1997, 278, 419–424.
  2. Tatemoto K: Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc Natl Acad Sci U S A1982, 79, 5485–5489.
  3. Sundler F, Bottcher G, Ekbald E, Hakanson R: PP, PPY and NPY: Occurrence and distribution in the periphery, In: The biology of neuropeptide Y and related peptides. Eds. Colmers WF, Wahlstead C, Humana Press, Totowa 1993, 1.
  4. Morris MJ, Russell AE, Kapoor V, Cain MD, Elliott JM, West MJ, Wing LM, Chalmers JP: Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J Auton Nerv Syst 1986, 17, 143–149.
  5. Pernow J, Lundberg JM, Kaijser L, Hjemdahl P, Theodorsson−Norheim E, Martinsson A, Pernow B: Plasma neuropeptide Y−like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. Clin Physiol 1986, 6, 561–578.
  6. Michel MC, Rascher W: Neuropeptide Y: a possible role in hypertension? J Hypertens 1995, 13, 385–395.
  7. Ng AV, Callister R, Johnson DG, Seals DR: Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension 1993, 21, 498–503.
  8. Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Ishii M: Age−related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension 1989, 13, 870–877.
  9. Veith RC, Featherstone JA, Linares OA, Halter JB: Age differences in plasma norepinephrine kinetics in humans. J Gerontl 1986, 41, 319–324.
  10. Esler M, Hastings J, Lambert G, Kaye D, Jennings G, Seals DR: The influence of aging on the human sympathetic nervous system and brain norepinephrine turnover. Am J Physiol Integrative Comp Physiol 2002, 282, R909–R916.
  11. Chiodera P, Volpi R, Pilla S, Cataldo S, Coiro V: Decline in circulating neuropeptide levels in normal elderly human subjects. Eur J Endocrinol 2000, 143, 715–716.
  12. Baranowska B, Bik W, Baranowska−Bik A, Wolinska−Witort E, Szybinska A, Martynska L, Chmielowska M: Neuroendocrine control of metabolic homeostasis in polish centenarians. J Physiol Pharmacol 2006, 57, 55–61.
  13. Bald M, Gerigk M, Rascher W: Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure. Am J Kidney Dis 1997, 30, 23–27.
  14. Hegbrant J, Thysell H, Ekman R: Plasma levels of vasoactive regulatory peptides in patients receiving regular hemodialysis treatment. Scand J Urol Nephrol 1992, 26, 169–176.
  15. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Iellamo D, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS: Prospective study of neuropeptide Y as an adverse cardiovascular risk factor in end−stage renal disease. J Am Soc Nephrol 2003, 14, 2611–2617.
  16. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS: Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. J Hypertens 2003, 21, 1355–1362.
  17. Adamczak M, Kokot F, Witkowicz J, Więcek A: Plasma neuropeptide Y concentration in kidney transplant patients during the early posttransplant period. Ann Transplant 2004, 37, 72–75.
  18. Campese VM, Kogosov E: Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995, 25, 878–882.
  19. Ye S, Ozgur B, Campese VM: Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997, 51, 722–727.
  20. Converse RL, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad−Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992, 327, 1912–1918.
  21. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995, 25, 305–313.
  22. Ullman B, Pernow J, Lundberg JM, Astrom H, Bergfeldt L: Cardiovascular effects and cardiopulmonary plasma gradients following intravenous infusion of neuropeptide Y in humans: negative dromotropic effect on atrioventricular node conduction. Clin Sci (Lond) 2002, 103, 535–542.
  23. Zukowska−Grojec Z, Haass M, Bayorh MA: Neuropeptide Y and peptide YY mediate nonadrenergic vasoconstriction and modulate sympathetic responses in rats. Regul Pept 1986, 15, 99–110.
  24. Oberhauser V, Vonend O, Rump LC: Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2−receptors. J Am Soc Nephrol 1999, 10, 1179–1185.
  25. Wocial B, Ignatowska−Switalska H, Pruszczyk P, Jedrusik P, Januszewicz A, Lapinski M, Januszewicz W, Zukowska−Grojec Z: Plasma neuropeptide Y and catecholamines in women and men with essential hypertension. Blood Press 1995, 4, 143–147.
  26. Halawa B, Salomon P: Concentration of neuropeptide Y in serum of patients with essential hypertension. Pol Arch Med Wewn 1996, 95, 420–426.
  27. Erlinge D, Ekman R, Thulin T, Edvinsson L: Neuropeptide Y−like immunoreactivity and hypertension. J Hypertens 1992, 10, 1221–1225.
© Wroclaw Medical University